178 related articles for article (PubMed ID: 34128073)
21. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
[TBL] [Abstract][Full Text] [Related]
22. Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma.
Baser ME; Poussaint TY
J Med Genet; 2006 Mar; 43(3):285-7. PubMed ID: 15980114
[TBL] [Abstract][Full Text] [Related]
23. The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas.
Kirches E; Steffen T; Waldt N; Hebert E; Pachow D; Wilisch-Neumann A; Keilhoff G; Schneider T; Braunsdorf WEK; Warnke JP; Mawrin C
J Neurooncol; 2018 Jun; 138(2):251-259. PubMed ID: 29468444
[TBL] [Abstract][Full Text] [Related]
24. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature.
Elbabaa SK; Gokden M; Crawford JR; Kesari S; Saad AG
J Neurosurg Pediatr; 2012 Oct; 10(4):281-90. PubMed ID: 22900483
[TBL] [Abstract][Full Text] [Related]
25. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
[TBL] [Abstract][Full Text] [Related]
27. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis.
Tauziede-Espariat A; Parfait B; Besnard A; Lacombe J; Pallud J; Tazi S; Puget S; Lot G; Terris B; Cohen J; Vidaud M; Figarella-Branger D; Monnien F; Polivka M; Adle-Biassette H; Varlet P
Brain Pathol; 2018 Jul; 28(4):466-474. PubMed ID: 28474749
[TBL] [Abstract][Full Text] [Related]
28. Pediatric meningiomas an aggressive subset: a clinicopathological and immunohistochemical study.
Hui M; Uppin MS; Saradhi MV; Sahu BP; Purohit AK; Sundaram C
J Postgrad Med; 2015; 61(1):32-5. PubMed ID: 25511215
[TBL] [Abstract][Full Text] [Related]
29. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
30. A genetic strategy to overcome the senescence of primary meningioma cell cultures.
Baia GS; Slocum AL; Hyer JD; Misra A; Sehati N; VandenBerg SR; Feuerstein BG; Deen DF; McDermott MW; Lal A
J Neurooncol; 2006 Jun; 78(2):113-21. PubMed ID: 16554968
[TBL] [Abstract][Full Text] [Related]
31. Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis.
Yamashita D; Suehiro S; Kohno S; Ohue S; Nakamura Y; Kouno D; Ohtsuka Y; Nishikawa M; Matsumoto S; Bernstock JD; Harada S; Mizuno Y; Kitazawa R; Ohnishi T; Kunieda T
Neurosurg Rev; 2021 Jun; 44(3):1591-1600. PubMed ID: 32671693
[TBL] [Abstract][Full Text] [Related]
32. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
34. Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas.
Pfisterer WK; Nieman RA; Scheck AC; Coons SW; Spetzler RF; Preul MC
Neurosurg Focus; 2010 Jan; 28(1):E12. PubMed ID: 20043716
[TBL] [Abstract][Full Text] [Related]
35. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas.
Lamszus K; Kluwe L; Matschke J; Meissner H; Laas R; Westphal M
Cancer Genet Cytogenet; 1999 Apr; 110(2):103-10. PubMed ID: 10214357
[TBL] [Abstract][Full Text] [Related]
36. Altered expression of beta-catenin/E-cadherin in meningiomas.
Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E
Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
[TBL] [Abstract][Full Text] [Related]
38. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetics of meningiomas.
Ragel BT; Jensen RL
Neurosurg Focus; 2005 Nov; 19(5):E9. PubMed ID: 16398473
[TBL] [Abstract][Full Text] [Related]
40. Molecular and genetic profiles of radiographically defined de novo meningiomas.
Kitamura Y; Sasaki H; Yoshida K
J Neurooncol; 2012 May; 108(1):37-44. PubMed ID: 22274402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
